Has Thomas Guttuso, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,297 in general payments to Thomas Guttuso, MD across 68 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Thomas Guttuso, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Thomas Guttuso, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Thomas Guttuso, MD

Neurology · Buffalo, NYNPI 1134192404

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,700 of the $18,297 with a category attached, or 85.8%. Acorda Therapeutics, Inc accounts for 94.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $16,106 and has fallen 98.5% since, to $235 in 2025.

$18,297in general payments, 2019–2025

Across 68 payments — averaging $269.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Acorda Therapeutics, Inc$17K
MDD US Operations, LLC$278
AbbVie$179
Teva Pharmaceuticals USA, Inc.$166
Medtronic$158
Neurocrine Biosciences, Inc.$82
plus $206 from 6 others

$177,537in research payments, 2019–2025

Across 10 payments — averaging $17,754 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

UCB SA$172K
Biogen$6K

What the payments were for

Speaking & faculty fees$15,70086%
Travel & lodging$8845%
Food & beverage$1,7029%
Education$110%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Acorda Therapeutics, Inc	19	$17,228
MDD US Operations, LLC	16	$278
AbbVie	7	$179
Teva Pharmaceuticals USA, Inc.	8	$166
Medtronic	1	$158
Neurocrine Biosciences, Inc.	4	$82
Supernus Pharmaceuticals, Inc.	3	$72
UCB, Inc.	2	$44
Greenwich Biosciences, Inc.	1	$31
Eisai Inc.	1	$30
GE HealthCare	2	$18
Travere Therapeutics, Inc.	4	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INBRIJA$16,738
PERCEPT PC BRAINSENSE$158

How this compares

$18,297 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York →

Medicare billing

Part B allowed, 2024

$89,695

Medicare patients

Services billed

10,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50	13	$82,985
Carbidopa-LevodopaCarbidopa/Levodopa	780	$63,473
Rasagiline Mesylate	129	$28,778
RytaryCarbidopa/Levodopa	12	$24,111
Selegiline Hcl	92	$10,451
AmantadineAmantadine Hcl	144	$5,584
Rivastigmine	17	$4,540
Carbidopa-Levodopa ErCarbidopa/Levodopa	54	$3,448
Fludrocortisone Acetate	56	$3,175
Primidone	84	$3,079
Gabapentin	166	$2,370
Propranolol Hcl ErPropranolol Hcl	49	$2,180
Pramipexole DihydrochloridePramipexole Di-Hcl	72	$2,068
Midodrine Hcl	27	$1,614
Donepezil Hcl	133	$1,536

Paid to pharmacies, not to this prescriber.

Other neurology in Buffalo

Gil WolfeBuffalo$617K
David HojnackiBuffalo$480K
Bianca Weinstock GuttmanBuffalo$288K
Idan SharonBrooklyn$2.1M
Allan PerelStaten Island$1.7M
Nicolas SaikaliAmherst$1.5M
David KreitzmanCommack$1.5M
Charles ArgoffAlbany$1.2M
Stephen KriegerNew York$1.1M
Robert FeketeHawthorne$1M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →